No one knows the size of this last(!) offering before Phase 3 results. I guess it will be at $5. If its more than $5, this will skyrocket in the morning. If its less than $5 (which I doubt so), grab all you can.
The outpatient treatment of opioid addiction with daily dosed sublingual buprenorphine formulations represented a $1.3 billion market in the U.S. in 2011, and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.
TTNP had successful Phase III results and NDA submitted and asked priority review... and Partnership is behind the scene now.
Twisting question but irrelevant. Both are separate issues. Saying so, Iam not ALXA lover, but it has all the reason to go to a buck soon.
"""If Adasuve gains FDA approval, Alexza “would still need a U.S. partner and/or to raise substantial cash to fund the launch of Adasuve, which should limit near-term upside,” Kantor said."""
This is the reality. May be green for few hrs IMO.
brook, you didn't get the point. I didnot say somebody is selling because of some 'hidden' bad date undisclosed by mngt. Its not that. Iam saying why its still limping at 1.2s? May be Symphony OPtions exercising. I have no idea. But, Mngt knew the reason.
may be MMs getting cheaper shares before unleashing this dog?
Trigger stoploss and add more for a potential catalyst in a month time.